Home | Welcome to Contract Pharma   
Last Updated Wednesday, April 23 2014
Print

Financial Report: Evotec 3Q



Published November 8, 2012
Evotec

3Q Revenues: €22.2 million (-16%)

3Q Earnings: €5.9 million (-30%)

YTD Revenues: €64.2 million (+8%)

YTD Earnings: €7.5 million (-18%)

Comments: YTD growth was driven by an increase in revenues from the company’s drug discovery alliances, Andromeda/Teva, Boehringer Ingelheim (€2.5 million) and Novartis, and revenues from upfront payments from the CureBeta partnership with Janssen and contributions from acquisitions of Evotec Munich and Evotec San Francisco.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On